###begin article-title 0
###xml 15 21 15 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 130 134 130 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
Implication of BRCA2 -26G>A 5' untranslated region polymorphism in susceptibility to sporadic breast cancer and its modulation by p53 codon 72 Arg>Pro polymorphism
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
###xml 60 66 60 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 273 279 273 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 450 454 450 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
The absence of mutation or promoter hypermethylation in the BRCA2 gene in the majority of breast cancer cases has indicated alternative ways of its involvement, deregulated expression being one possibility. We show how a polymorphism in the 5' untranslated region (UTR) of BRCA2 can serve as one such factor. Based on the hypothesis that variants of genes involved in the same pathway can influence the risk provided for breast cancer, the status of p53 codon 72 polymorphism was also investigated and a possible interaction between the polymorphisms was examined.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 154 159 154 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 335 343 <span type="species:ncbi:9606">patients</span>
The luciferase reporter assay followed by RNA secondary structure analysis was used for the functional characterization of -26 5' UTR G>A polymorphism in BRCA2. The genotype and the allele frequency for the polymorphisms were determined and relative risk adjusted for age was calculated in a case-control study of 576 individuals (243 patients and 333 controls) from north India.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 38 44 38 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 171 173 171 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 192 194 192 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 524 525 524 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 525 554 525 554 <sub xmlns:xlink="http://www.w3.org/1999/xlink">heterozygote advantage model </sub>
###xml 714 718 714 718 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 797 799 797 799 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 978 980 978 980 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 787 795 <span type="species:ncbi:9606">patients</span>
-26 G>A polymorphism in the 5' UTR of BRCA2 was found to be functional whereby the A allele increased the reporter gene expression by twice that of the G allele in MCF-7 (P = 0.003) and HeLa (P = 0.013) cells. RNA secondary structure analysis by two different programs predicted the A allele to alter the stability of a loop in the vicinity of the translation start site. Its direct implication in breast cancer became evident by a case-control study in which the heterozygous genotype was found to be protective in nature (Pheterozygote advantage model = 0.0005, odds ratio [OR] = 0.5, 95% confidence interval [CI] = 0.4 to 0.8), which was further supported by trends observed in a genomic instability study. The p53 codon 72 Arg homozygous genotype was found to be over-represented in patients (P = 0.0005, OR = 2.3, 95% CI = 1.4 to 3.6). The interaction study indicated an increased protection under simultaneous presence of protector genotypes of both the polymorphic loci (P = 0.0001, OR = 0.2, 95% CI = 0.1 to 0.4).
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 48 54 48 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 121 127 121 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 322 325 322 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
Our study shows that -26 5' UTR polymorphism in BRCA2 can modulate the fine-tuned regulation of the multifunctional gene BRCA2 and renders risk or protection according to the genotype status in the sporadic form of breast cancer, which is further influenced by the germline genetic backgrounds of codon 72 polymorphism of p53.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 67 68 67 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 155 156 155 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 172 173 172 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 174 175 174 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 190 191 190 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 192 193 192 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 211 212 211 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 243 244 243 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 352 358 352 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 429 435 429 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 442 443 442 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 574 576 574 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 577 579 577 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 654 660 654 660 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 775 781 775 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 849 851 849 851 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 873 875 873 875 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 876 878 876 878 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 943 945 943 945 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 989 995 989 995 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
BRCA2, since its discovery as a breast cancer susceptibility gene [1], has been implicated in processes fundamental to all cells, including proliferation [2], development [3,4], DNA repair [5,6], transcription [7], and centrosome duplication [8]. Consistent with the tumor suppressor status of the gene, tumors that develop in carriers of heterozygous BRCA2 mutations are frequently associated with loss of heterozygosity at the BRCA2 locus [9]. Inherited mutations in the gene continue to be associated with the familial form of breast, ovarian, and other types of cancer [10,11], which represent only a small proportion of the total cases. The role of BRCA2 in the development of the sporadic form of breast cancer remains undefined. Although loss of heterozygosity of the BRCA2 locus has been detected in more than 50% of sporadic breast tumors [12], somatic mutations [13-15] or inactivation by methylation has been either absent or rare [16]. The involvement of altered expression of BRCA2 in the development of sporadic breast cancer is a possibility.
###end p 11
###begin p 12
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 197 202 197 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 379 380 379 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 529 535 529 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 545 547 545 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 569 571 569 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 619 625 619 625 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 677 683 677 683 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 721 725 721 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 799 805 799 805 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 842 845 842 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 925 929 925 929 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 930 931 930 931 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 932 934 932 934 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 935 937 935 937 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 944 948 944 948 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 958 964 958 964 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 1008 1010 1008 1010 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
BRCA2 gene expression, owing to its functional relevance, is tightly regulated by several known and unknown factors, which in turn could be candidates responsible for the deregulated expression of BRCA2, thus leading to cancer. Its expression is elevated indirectly in response to the mitogenic activity of estrogen, which has been associated with progression of the cell cycle [3]. Cell cycle-dependent expression has been associated with binding of the upstream stimulatory factor protein and EIf-1 transcription factor to the BRCA2 promoter [17]. Wu and colleagues [18] provided evidence for direct induction of the BRCA2 promoter through binding of nuclear factor-kappa B. BRCA2 shares a complex regulatory loop with p53 that may be directly associated with the cellular response to DNA damage. BRCA2 limits the length or severity of the p53-mediated cell cycle-arrest phenotype by inhibiting transactivation activity of p53 [4,19,20], and p53 represses BRCA2 expression in response to genotoxic stress [21].
###end p 12
###begin p 13
###xml 52 58 52 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 356 362 356 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 655 661 655 661 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 665 669 665 669 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 738 742 738 742 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 773 775 773 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 776 778 776 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 809 815 809 815 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
Thus, polymorphisms in the regulatory region of the BRCA2 gene, which can modulate the fine-tuned regulation of its expression, are logical candidates to provide risk for breast cancer. In the present study, we ascertain the functional role of a common polymorphism -26 G>A (GenBank accession number , rs1799943) in the 5' untranslated region (UTR) of the BRCA2 gene and test its implications in breast cancer pathogenesis. Furthermore, it has been hypothesized that breast cancer is a complex disease and that variants in multiple biologically related genes combine to affect the risk. In light of the fact that there is a functional interaction between BRCA2 and p53 in the DNA damage response pathway, the status of the widely studied p53 codon 72 Arg/Pro polymorphism [22-41] and its interaction with -26 BRCA2 polymorphism was also evaluated.
###end p 13
###begin title 14
Materials and methods
###end title 14
###begin title 15
###xml 11 17 11 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
Cloning of BRCA2 promoter + 5' UTR
###end title 15
###begin p 16
###xml 24 30 24 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
The minimal promoter of BRCA2 and the 5' UTR with A or G at the -26 position (HUGO nomenclature) was amplified from already genotyped healthy control DNA, using the following primers: forward 5'-GATACTGACGGTTGGGATG-3' and reverse 5'-ATTTTTACCTACGATATTCCT-3' with long polymerase chain reaction (PCR) enzyme mix (Fermentas Canada Inc., Burlington, ON, Canada). The amplified product was cloned in TOPO cloning vector (Invitrogen Corporation, Carlsbad, CA, USA). It was then digested with Kpn and XhoI (Fermentas Canada Inc.) for cloning into pGL3 basic vector (Promega Corporation, Madison, WI, USA). Sequencing (Applied Biosystems, Foster City, CA, USA) was performed to confirm positive clones and the change at -26 5' UTR.
###end p 16
###begin title 17
Cell culture
###end title 17
###begin p 18
###xml 208 210 202 204 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 151 157 <span type="species:ncbi:9913">bovine</span>
###xml 158 162 <span type="species:ncbi:9913">calf</span>
Human breast adenocarcinoma MCF-7 and cervical carcinoma HeLa cells were propagated in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% bovine calf serum and maintained at 37degreesC with 5% CO2 (cell culture reagents were obtained from Life Technologies, Inc., now part of Invitrogen Corporation).
###end p 18
###begin title 19
Transient transfection and luciferase assays
###end title 19
###begin p 20
###xml 168 170 168 170 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5 </sup>
###xml 413 419 412 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 460 468 458 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Renilla </italic>
###xml 575 583 572 580 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Renilla </italic>
###xml 772 780 769 777 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Renilla </italic>
###xml 1303 1311 1297 1305 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Renilla </italic>
###xml 231 237 <span type="species:ncbi:9913">bovine</span>
###xml 238 242 <span type="species:ncbi:9913">calf</span>
Plasmid DNA was isolated using the plasmid maxi kit (Qiagen Inc., Valencia, CA, USA) for transient transfection. MCF-7 and HeLa cells were plated at a density of 1 x 105 cells per well in six-well plates and grown in DMEM with 10% bovine calf serum overnight, prior to transfection. All transfections were carried out using PolyFect (Qiagen Inc.) according to the manufacturer's instructions. A total of 1 mug of BRCA2 promoter construct and 0.1 mug of pRL-TK Renilla luciferase vector (Promega Corporation) with 5 muL of PolyFect were used for each transfection. The pRL-TK Renilla luciferase activity was used as a control for transfection efficiency. Each transfection experiment was performed in duplicate and repeated a minimum of three times. Firefly luciferase and Renilla luciferase assays were performed using the Dual-Luciferase Reporter Assay System (Promega Corporation). Approximately 48 hours after transfection, cells were washed twice with 1x phosphate-buffered saline and harvested with 600 muL of passive lysis buffer (Promega Corporation). Cell lysates were cleared by centrifugation, and 5 muL was added to 100 muL of firefly luciferase substrate, and light units were measured in a luminometer (TD-20/20, DLReady; Turner Designs, Inc., Sunnyvale, CA, USA, and Promega Corporation). Renilla luciferase activities were measured in the same tube after addition of 100 muL of Stop and Glo reagent. For adriamycin (ADR) (Sigma-Aldrich, St. Louis, MO, USA) treatment experiments, MCF-7 and HeLa cells were transfected, grown for 24 hours, and exposed to 0, 1, and 2.5 muM ADR for 1 hour in standard medium. The cells were washed with serum-free medium and incubated at 37degreesC in fresh culture medium for another 24 hours before harvesting for luciferase assay.
###end p 20
###begin title 21
Cases and controls
###end title 21
###begin p 22
###xml 128 134 128 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 154 158 154 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 182 190 <span type="species:ncbi:9606">patients</span>
###xml 314 322 <span type="species:ncbi:9606">patients</span>
A total of 576 peripheral blood samples from north India were studied for the germline status of polymorphisms in the 5' UTR of BRCA2 and codon 72 of the p53 gene. This included 243 patients with sporadic breast cancer and 333 unrelated, healthy female controls with no history of breast cancer. In 145 of the 243 patients, tumors along with corresponding blood samples and adjacent normal tissues (only in 5 cases in which blood sample was not available) were also obtained to assess the somatic status of the mentioned amplified regions and genomic instability for the informative markers (mentioned below) established over a period of time in our laboratory in a pair study. Care was taken that both cases and controls were ethnically and geographically matched. Prior approval was given by the Jawaharlal Nehru University ethical committee and the concerned subjects for sample collection and study. The tissue samples were frozen immediately after collection and stored at -80degreesC until use. DNA was extracted from the peripheral blood leucocytes and from tissues according to the standard phenol-chloroform method.
###end p 22
###begin title 23
Polymorphism study
###end title 23
###begin p 24
###xml 71 73 71 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 195 200 195 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
PCR was performed under conditions similar to those described earlier [42] with the following primer sequences (respective annealing temperatures are mentioned alongside): -26G>A polymorphism in BRCA2, forward 5'-CTC AGT CAC ATA ATA AGG AAT-3' and reverse 5'-ACA CTG TGA CGT ACT GGG TTT T-3' (55degreesC) and exon 4 codon 72 Arg>Pro polymorphism, forward 5'-TGC TCT TTT CAC CCA TCT AC-3' and reverse 5'-ATA CGG CCA GGC ATT GAA GT-3' (62degreesC). Thereafter, polymorphisms were detected by sequencing of their respective PCR products.
###end p 24
###begin title 25
Genomic instability analysis
###end title 25
###begin p 26
###xml 41 45 41 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 278 280 278 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
Mutation analysis of exons 5 to 8 of the p53 gene and allelic imbalance study using three informative markers each in chromosome 16 (D16S3082, D16S423, and D16S413) and chromosome 17 (D17S379, D17S934, and D17S787) were carried out according to the procedure mentioned earlier [42] in 145 of 243 paired samples.
###end p 26
###begin title 27
Statistical analysis
###end title 27
###begin p 28
###xml 221 223 221 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 508 510 508 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 577 579 577 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 627 629 627 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 53 61 <span type="species:ncbi:9606">patients</span>
###xml 176 184 <span type="species:ncbi:9606">patients</span>
First, overall genotype frequencies of breast cancer patients and control subjects were compared using the 3 x 2 chi-square test. Once a significant overall difference between patients and controls subjects was detected (P < 0.05), the individual genotypes were analyzed using an unconditional logistic regression model with correction for age using the SPSS statistical package, version 10 (SPSS Inc., Chicago, IL, USA). To compare the relative luciferase activity and the genomic instability analysis, the t test and the chi-square/Fisher exact test were used, respectively [43]. Statistical significance was considered at a P value of less than or equal to 0.05.
###end p 28
###begin title 29
Results
###end title 29
###begin title 30
Effect of 5' UTR -26 G>A polymorphism on reporter gene expression
###end title 30
###begin p 31
###xml 37 43 37 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 207 208 207 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 350 352 350 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 379 381 379 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 664 665 664 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 709 713 709 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
To study the effect on expression of BRCA2 5' UTR -26 G>A polymorphism, HeLa and MCF-7 cells were transiently transfected with reporter gene construct (pGL3Basic) with A or G at the polymorphic site. Figure 1 (upper panel) shows how the construct containing the A allele showed significantly higher expression than the one with the G allele in HeLa (P = 0.013) as well as MCF-7 (P = 0.003) cell lines. Both HeLa and MCF-7 cells exposed to various concentrations of ADR for 1 hour after 24 hours of transfection downregulated the overall expression as expected, but the trend of A allele expressing higher than its alternative G allelic form was maintained (Figure 1, lower panel). The increased activation of p53 by ADR treatment was observed in our experiments as well (data not shown).
###end p 31
###begin p 32
###xml 34 40 34 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
Reporter gene assay with chimeric BRCA2 promoter and 5' untranslated region (UTR) with A or G at the -26 position (upper panel) and the effect of increasing the dose of adriamycin (0, 1, and 2.5 muM) (lower panel).
###end p 32
###begin title 33
###xml 46 52 46 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
Computational assessment of the regulation of BRCA2 expression by -26 G>A polymorphism
###end title 33
###begin p 34
###xml 141 143 141 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 205 206 205 206 <underline xmlns:xlink="http://www.w3.org/1999/xlink">G</underline>
###xml 218 219 218 219 <underline xmlns:xlink="http://www.w3.org/1999/xlink">A</underline>
###xml 498 500 498 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 1169 1171 1161 1163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 1242 1243 1234 1235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
The analysis of the polymorphic region for the presence of a putative transcription factor binding site by means of the AliBaba 2.1 program [44] revealed that the G>A change creates a C/EBP alpha (TTTACCAAGC > TTTACCAAAC) binding site. The presence of an OCT1 binding site almost overlapping to this region, however, was not affected by the polymorphism. The analysis of the complete 5' UTR with G or A at the -26 position for RNA secondary structure folding by RNAstructure program (version 4.3) [45] depicted a 40-base pair (bp) loop formation in the vicinity of the translation start site and this structure changed with the change of the G>A base at the position. Furthermore, RNA secondary structure folding of the 40-bp loop with free energy change (DeltaG) calculation, when compared using two different programs, showed a similar trend in the results obtained. The base substitution brought a change in the structure, and the presence of G at the -26 position significantly increased DeltaG (-9.4 kcal/mole versus -5.1 kcal/mole by RNAstructure V4.3 and -10.46 kcal/mole versus -7.10 kcal/mole by VRNAAFOLD, The European Molecular Biology Open Software Suite) [46] when compared with that of the A allele at the same position (Figure 2).
###end p 34
###begin p 35
Effect of -26 G/A polymorphism on the 5' untranslated region secondary structure of RNA and stability analyzed by the RNAstructure program (version 4.3) and VRNAAFOLD (The European Molecular Biology Open Software Suite). The -26 position with G or A is indicated by arrows.
###end p 35
###begin title 36
5' UTR -26 G>A polymorphism in association with breast cancer risk
###end title 36
###begin p 37
###xml 193 194 193 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 397 399 397 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 531 532 531 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 532 561 532 561 <sub xmlns:xlink="http://www.w3.org/1999/xlink">heterozygote advantage model </sub>
###xml 779 781 779 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 849 851 849 851 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 346 354 <span type="species:ncbi:9606">patients</span>
To further assess the relevance of this functional polymorphism, a preliminary case-control study was undertaken to assess the effect of -26 G>A on sporadic breast cancer susceptibility. Table 1 presents the details of the genotype and allele frequencies along with the risk calculations. The overall distribution of genotype frequencies between patients and controls was found to be significant (P = 0.001). Surprisingly, the heterozygous genotype provided approximately twice the protection than the common G/G homozygous state (Pheterozygote advantage model = 0.0005, odds ratio [OR] = 0.5, 95% confidence interval [CI] = 0.4 to 0.8). However, there was no significant difference in the distribution of the A/A homozygous genotype in comparison with the G/G homozygous state (P = 0.677, OR = 1.1, 95% CI = 0.6 to 2.1) and the allele frequencies (P = 0.092).
###end p 37
###begin p 38
###xml 35 41 35 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 49 53 49 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 102 110 <span type="species:ncbi:9606">patients</span>
Genotype and allele frequencies of BRCA2 -26 and p53 codon 72 polymorphisms in sporadic breast cancer patients and normal controls
###end p 38
###begin p 39
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1 3 1 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 49 50 49 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 50 52 50 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 175 178 175 178 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c,d</sup>
###xml 178 180 178 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 542 543 542 543 <sup xmlns:xlink="http://www.w3.org/1999/xlink">e</sup>
###xml 543 545 543 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 152 160 <span type="species:ncbi:9606">patients</span>
###xml 296 304 <span type="species:ncbi:9606">patients</span>
aP value for Hardy-Weinberg equilibrium testing. bP value for 3 x 2 chi-square test of comparison of overall genotype frequencies between breast cancer patients and controls. c,dP values and corresponding age-adjusted ORs with 95% CIs for comparison of genotype frequencies between breast cancer patients and controls by logistic regression (not adjusted for age in allele frequency comparisons); the referent genotypes were considered on the basis of highest proportion of a homozygous genotype at any particular locus in the control group. eP values continue to remain significant after applying Bonferroni correction of 2 (2 single-nucleotide polymorphisms tested in a case-control group) to correct for multiple comparisons. CI, confidence interval; OR, odds ratio.
###end p 39
###begin title 40
Heterozygous genotype in association with genomic instability
###end title 40
###begin p 41
###xml 32 38 32 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 288 292 288 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 343 344 343 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 632 636 632 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 713 714 713 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 787 789 787 789 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 798 800 798 800 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 853 855 853 855 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 864 866 864 866 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 962 964 962 964 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1050 1052 1050 1052 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1066 1070 1066 1070 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 1136 1142 1136 1142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 1160 1164 1160 1164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
To test the hypothesis that the BRCA2 heterozygous genotype provides protection in comparison with either of the homozygous genotypes at the -26 position in the 5' UTR, allelic imbalance for the selected informative markers in chromosomes 16 and 17 was studied along with mutation in the p53 gene (mutation details provided in Additional File 1) in a panel of normal and tumor tissues already characterized for the polymorphism. Interestingly, the tumors with a heterozygous background for the polymorphism showed a decreased frequency of allelic imbalance for the three informative markers each on chromosomes 16 and 17 as well as p53 somatic mutations when compared with either of the homozygous tumors (Figure 3). Further delineation of genotype comparisons showed that GG versus GA (P = 0.038, P = 0.009) was significant compared with AA versus GA (P = 0.771, P = 0.129) for allelic imbalance in chromosomes 16 and 17, respectively. Inversely, AA versus GA (P = 0.076) showed a nonsignificant trend toward association compared with GG versus GA (P = 0.613) when p53 somatic mutations were compared. Incidentally, both the 5' UTR of BRCA2 and exon 4 of the p53 gene did not show any somatic variation in tumor tissues of the studied samples.
###end p 41
###begin p 42
###xml 80 84 80 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 122 124 122 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Comparison of allelic imbalance in chromosomes 16 and 17 along with mutation in p53 with -26 G>A polymorphism background. P values given are for overall distribution, G/G versus G/A, and A/A versus G/A.
###end p 42
###begin title 43
###xml 10 14 10 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 69 79 69 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 -26 </italic>
Status of p53 codon 72 Arg/Pro polymorphism and its interaction with BRCA2 -26 polymorphism
###end title 43
###begin p 44
###xml 137 139 137 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 153 157 153 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 191 193 191 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 261 262 261 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 262 275 262 275 <sub xmlns:xlink="http://www.w3.org/1999/xlink">allele model </sub>
###xml 371 372 371 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 442 446 442 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 450 456 450 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 537 543 537 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 652 654 652 654 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 702 703 702 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 74 82 <span type="species:ncbi:9606">patients</span>
###xml 355 363 <span type="species:ncbi:9606">patients</span>
The overall genotype frequency distribution at the codon 72 locus between patients and controls was found to be significantly different (P = 0.001). The p53 codon 72 Arg homozygous genotype (P = 0.0005, OR = 2.3, 95% CI = 1.4 to 3.6) as well as the Arg allele (Pallele model = 0.0002, OR = 1.7, 95% CI = 1.2 to 2.0) were significantly over-represented in patients (Table 1). Stratified genotypic data to assess the combined influence of both p53 and BRCA2 polymorphisms on breast cancer risk revealed that the G/A at the -26 position of BRCA2 in combination with the Pro allele at the codon 72 locus provided fivefold protection against breast cancer (P = 0.0001, OR = 0.2, 95% CI = 0.1 to 0.4) (Table 2).
###end p 44
###begin p 45
###xml 39 43 39 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 56 62 56 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 92 100 <span type="species:ncbi:9606">patients</span>
Interaction between the polymorphisms: p53 codon 72 and BRCA2 -26 in sporadic breast cancer patients and normal controls
###end p 45
###begin p 46
###xml 0 3 0 3 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a,b</sup>
###xml 3 5 3 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 182 183 182 183 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 183 185 183 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 136 144 <span type="species:ncbi:9606">patients</span>
a,bP values and corresponding age-adjusted ORs with 95% CIs for comparison of combination of genotype frequencies between breast cancer patients and controls by logistic regression. cP values continue to remain significant after applying Bonferroni correction of 9 (9 combinations tested in a case-control group) to correct for multiple comparisons. CI, confidence interval; OR, odds ratio.
###end p 46
###begin title 47
Discussion
###end title 47
###begin p 48
###xml 46 52 46 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 166 168 166 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 169 171 169 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 230 236 230 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 365 371 365 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 457 463 457 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 545 549 545 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
The failure of mutational inactivation of the BRCA2 gene to show an association with breast cancer, specifically the sporadic form, in two recent reports from India [14,15] indicated the need to further explore the involvement of BRCA2 in breast cancer susceptibility, with altered expression as a possibility. We propose that -26 G>A polymorphism in the 5' UTR of BRCA2 has a regulatory role and acts as one of the risk factors, modulating the function of BRCA2 in breast cancer pathogenesis, further influenced by codon 72 polymorphism in the p53 gene.
###end p 48
###begin p 49
###xml 70 76 70 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 285 291 285 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 402 408 402 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 487 493 487 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 513 517 513 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 529 531 529 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1284 1289 1284 1289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 1374 1376 1374 1376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 1389 1391 1389 1391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 1486 1494 1486 1494 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
The functional characterization of the common G>A polymorphism in the BRCA2 -26 5' UTR by reporter assay revealed that the A allele led to higher expression than the G allele in both HeLa and MCF-7 cell lines. This suggests that the polymorphism might have a role in the regulation of BRCA2 expression. Upholding the same trend by ADR treatment further implied that the -26 polymorphism might regulate BRCA2 expression independent of other factors, specifically to the repression of the BRCA2 promoter by ADR via p53 activation [21]. A search for a consensus sequence for the putative transcription factor in the polymorphic site revealed the creation of a C/EBP alpha transcription binding site by the change from G>A in the -26 polymorphic position. However, the presence of an OCT1 binding site almost overlapping to this region, not affected by the polymorphism, makes the transcriptional control hypothesis an unlikely one, unless proven by the gel shift or chromatin immunoprecipitation assays. The analysis of the 5' UTR for the RNA secondary structure by two different programs showed that the presence of G at -26 stabilized the loop at the vicinity of the translation start site, which could decrease the efficiency of the translation and thereby decrease the expression of BRCA2. This finding of ours is supported by the classic work of Vega Laso and colleagues [47] and Kozak [48], who have argued that the extent of a hairpin negative effect on eukaryotic mRNA translation in vivo depends upon its stability and localization within the molecule.
###end p 49
###begin p 50
###xml 42 48 42 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 227 233 227 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 267 269 267 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 462 464 462 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 580 582 580 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 654 656 654 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 1197 1201 1197 1201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 1218 1219 1218 1219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1220 1222 1220 1222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1223 1225 1223 1225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1324 1326 1324 1326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 1327 1329 1327 1329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 1547 1551 1547 1551 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 1645 1651 1645 1651 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 1652 1653 1652 1653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1654 1656 1654 1656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1657 1659 1657 1659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1660 1662 1660 1662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 1663 1665 1663 1665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 1858 1864 1858 1864 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
The -26 G>A polymorphism in the 5' UTR of BRCA2 has been analyzed in some cancer types. In one study, the -26A allele was reported to show a borderline association with ovarian cancer, but similar results in breast cancer with BRCA1 mutation carriers were not found [49]. Another study showed a monotonic increase in the frequency of the heterozygous G/A genotype from the lowest to highest risk groups of esophageal squamous cell carcinoma from northern China [50]. Our observation supports a heterozygote-protective model, which has been well recognized in infectious diseases [51] and is consistent with the initial findings of Healey and colleagues [52] in sporadic breast cancer. An increased genomic instability in the homozygotes compared to heterozygotes substantiates the protective nature of the heterozygous genotype. The differential results of the association study as reported previously could be due to the outcome of various single-nucleotide polymorphism (SNP)-SNP and SNP-environment interactions, again modulated by population and disease type. Nevertheless, our observations of the A allele associated with higher expression and increased genomic instability via inhibition of p53 transactivation [4,19,20] and of the G allele with low expression impairing the DNA repair leading to genomic instability [53-55] apparently explain the risk provided by the homozygous state of the two alleles A and G to breast cancer. Our results also showed that either of the homozygous forms is associated with increased allelic imbalance or p53 mutations, which again is in line with the findings on consequences of aberrant expression of BRCA2 [4,19,20,53-55]. On the basis of these observations, it seems apparent that a germline heterozygosity status at -26 5' UTR may therefore confer a protective phenotype characterized by intermediate levels of BRCA2 expression and an optimal balanced DNA damage response, specifically to double-strand breaks.
###end p 50
###begin p 51
###xml 78 82 78 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 281 285 281 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 385 389 385 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 483 485 483 485 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 513 515 513 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 659 661 659 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 662 664 662 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 771 773 771 773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 956 958 956 958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 959 961 959 961 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 1035 1036 1035 1036 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2</xref>
###xml 1083 1089 1083 1089 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 1102 1106 1102 1106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 1197 1201 1197 1201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 1235 1241 1235 1241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
To test the SNP-SNP interaction model, functional polymorphism at codon 72 of p53 was considered based on the emerging hypothesis that variants in many genes along related biological pathways combine to influence breast cancer risk. The two alleles of the Arg72Pro polymorphism of p53 differ in their biological activities. The Pro allele is associated with increased transcription of p53 target genes via greater binding to transcriptional machinery and thus shows higher rates of G1 arrest than the Arg allele [22]. In contrast, the Pro allele is less efficient in suppressing transformation (likely due to reduced apoptotic potential) than the Arg allele [22-24], which could be due to efficient binding and regulation by iASPP (inhibitory member of the ASPP family) [25]. A summary of case-control reports on the association of codon 72 polymorphism with breast cancer across the globe, including our results, revealed an inconsistency in association [26-41], again pointing toward modulations by multiple factors (Additional File 2). Our analysis of the interaction between -26 BRCA2 and codon 72 p53 polymorphism showed that the simultaneous presence of protective genotypes, Pro/Pro at the p53 codon 72 locus and G/A at the -26 BRCA2 locus, rendered fivefold protection against breast cancer and was approximately twice of what each genotype rendered alone.
###end p 51
###begin title 52
Conclusion
###end title 52
###begin p 53
###xml 48 54 48 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 325 330 325 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 502 508 502 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 714 718 714 718 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 749 755 749 755 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 831 837 <span type="species:ncbi:9606">humans</span>
Our study shows that 5' UTR -26 polymorphism of BRCA2 might regulate its expression, albeit not at a transcriptional level, but at a post-transcriptional level affecting the translational efficiency. It is interesting to presume that the low-penetrating SNP can modulate the fine-tuned regulation of the multifunctional gene BRCA2, leading to the differential form of genomic instability and rendering risk to the sporadic form of breast cancer. This also provides an alternative to the involvement of BRCA2 in the sporadic form in which inactivation by somatic mutagenesis and methylation is known to be rare. The analysis also puts into perspective the functional implication of the dimorphic germline status of p53 in the background of 5' UTR of BRCA2 in sporadic breast cancer development and calls for more of such studies in humans to understand the epistatic effect of genetic backgrounds in the promotion and progression of the cancer.
###end p 53
###begin title 54
Abbreviations
###end title 54
###begin p 55
ADR = adriamycin; bp = base pair; CI = confidence interval; DMEM = Dulbecco's modified Eagle's medium; OR = odds ratio; PCR = polymerase chain reaction; SNP = single-nucleotide polymorphism; UTR = untranslated region.
###end p 55
###begin title 56
Competing interests
###end title 56
###begin p 57
The authors declare that they have no competing interests.
###end p 57
###begin title 58
Authors' contributions
###end title 58
###begin p 59
SG participated in the design of the experiments, experimental data acquisition, statistical analysis, and the writing of the draft. SB, SV, KD, and MR participated in the development of the study method and coordinated the collection of data. NB participated in the design of the experiments and the interpretation of data. PG, as clinician and surgeon, participated in the acquisition and interpretation of data. SH participated in the interpretation of data and gave critical suggestions. RB conceived of the study, participated in the design of the experiments and the interpretation of data, revised the draft critically for intellectual content, and gave final approval of the version to be published. All authors have read and approved the final manuscript.
###end p 59
###begin title 60
Supplementary Material
###end title 60
###begin title 61
Additional file 1
###end title 61
###begin p 62
###xml 119 127 <span type="species:ncbi:9606">patients</span>
Details of the somatic mutations found in the exons 5-8 (DNA binding domain) of the p53 gene in sporadic breast cancer patients
###end p 62
###begin p 63
Click here for file
###end p 63
###begin title 64
Additional file 2
###end title 64
###begin p 65
Summary of p53 codon 72 association studies in breast cancer across the globe
###end p 65
###begin p 66
Click here for file
###end p 66
###begin title 67
Acknowledgements
###end title 67
###begin p 68
###xml 22 29 <span type="species:ncbi:9606">patient</span>
###xml 572 577 <span type="species:ncbi:9606">Human</span>
The authors thank the patient and control subjects for their participation. The cooperation of Minmal S Ganesh and Durga Prasan from Dharamshila Cancer Hospital and Research Centre is acknowledged. The assistance of Purushottam M Kulkarni of the School of Social Sciences, Jawaharlal Nehru University, in statistical analysis is acknowledged. SG is grateful to the Council of Scientific and Industrial Research, New Delhi, India, for the pre-doctoral fellowship. RB was supported by a research grant from the University Grants Commission to the National Centre of Applied Human Genetics and the University with Potential of Excellence project.
###end p 68
###begin article-title 69
Identification of the breast cancer susceptibility gene BRCA2
###end article-title 69
###begin article-title 70
Cell cycle control of BRCA2
###end article-title 70
###begin article-title 71
Developmental expression of Brca2 colocalizes with Brca1 and is associated with proliferation and differentiation in multiple tissues
###end article-title 71
###begin article-title 72
###xml 72 76 <span type="species:ncbi:10090">mice</span>
Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2
###end article-title 72
###begin article-title 73
The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability
###end article-title 73
###begin article-title 74
Minding the gap: the underground functions of BRCA1 and BRCA2 at stalled replication forks
###end article-title 74
###begin article-title 75
Transcriptional activation functions in BRCA2
###end article-title 75
###begin article-title 76
Interference with BRCA2, which localizes to the centrosome during S and early M phase, leads to abnormal nuclear division
###end article-title 76
###begin article-title 77
Cancer susceptibility and the functions of BRCA1 and BRCA2
###end article-title 77
###begin article-title 78
Cancer risks among BRCA1 and BRCA2 mutation carriers
###end article-title 78
###begin article-title 79
The prevalence of BRCA2 mutations in familial pancreatic cancer
###end article-title 79
###begin article-title 80
###xml 55 60 <span type="species:ncbi:9606">human</span>
Prognostic value of loss of heterozygosity at BRCA2 in human breast carcinoma
###end article-title 80
###begin article-title 81
BRCA2 mutations in primary breast and ovarian cancers
###end article-title 81
###begin article-title 82
Novel germline mutations in the BRCA1 and BRCA2 genes in Indian breast and breast-ovarian cancer families
###end article-title 82
###begin article-title 83
Contribution of germline BRCA1 and BRCA2 sequence alterations to breast cancer in Northern India
###end article-title 83
###begin article-title 84
Absence of methylation of CpG dinucleotides within the promoter of the breast cancer susceptibility gene BRCA2 in normal tissues and in breast and ovarian cancers
###end article-title 84
###begin article-title 85
Isolation and initial characterization of the BRCA2 promoter
###end article-title 85
###begin article-title 86
Induction of the BRCA2 promoter by nuclear factor-kappa B
###end article-title 86
###begin article-title 87
The BRCA2 gene product functionally interacts with p53 and RAD51
###end article-title 87
###begin article-title 88
Involvement of Brca2 in DNA repair
###end article-title 88
###begin article-title 89
p53 mediates repression of the BRCA2 promoter and down-regulation of BRCA2 mRNA and protein levels in response to DNA damage
###end article-title 89
###begin article-title 90
p53 polymorphic variants at codon 72 exert different effects on cell cycle progression
###end article-title 90
###begin article-title 91
Two polymorphic variants of wild-type p53 differ biochemically and biologically
###end article-title 91
###begin article-title 92
The codon 72 polymorphic variants of p53 have markedly different apoptotic potential
###end article-title 92
###begin article-title 93
iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53
###end article-title 93
###begin article-title 94
p53 polymorphisms and haplotypes in breast cancer
###end article-title 94
###begin article-title 95
p53 haplotype determination in breast cancer
###end article-title 95
###begin article-title 96
Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer
###end article-title 96
###begin article-title 97
p53 codon 72 polymorphism as a risk factor in the development of breast cancer
###end article-title 97
###begin article-title 98
P53 codon 72 polymorphism in breast cancer
###end article-title 98
###begin article-title 99
The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece
###end article-title 99
###begin article-title 100
###xml 74 79 <span type="species:ncbi:9606">women</span>
The R72P P53 mutation is associated with familial breast cancer in Jewish women
###end article-title 100
###begin article-title 101
Evidence for an association of TP53 codon 72 polymorphism with breast cancer risk
###end article-title 101
###begin article-title 102
Polymorphism of the p53 codon 72 Arg/Pro and the risk of HPV type 16/18-associated cervical and oral cancer in India
###end article-title 102
###begin article-title 103
###xml 113 121 <span type="species:ncbi:9606">patients</span>
No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients
###end article-title 103
###begin article-title 104
Evidence against involvement of p53 polymorphism in breast cancer predisposition
###end article-title 104
###begin article-title 105
###xml 114 119 <span type="species:ncbi:9606">women</span>
Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women
###end article-title 105
###begin article-title 106
Polymorphism of p53 gene in Jordanian population and possible associations with breast cancer and lung adenocarcinoma
###end article-title 106
###begin article-title 107
###xml 14 22 <span type="species:ncbi:9606">patients</span>
Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival
###end article-title 107
###begin article-title 108
###xml 82 87 <span type="species:ncbi:9606">women</span>
Polymorphism of TP53 codon 72 showed no association with breast cancer in Iranian women
###end article-title 108
###begin article-title 109
The p53 Arg72Pro and MDM2 -309 polymorphisms and risk of breast cancer in the nurses' health studies
###end article-title 109
###begin article-title 110
p53 mutation profile of squamous cell carcinomas of the esophagus in Kashmir (India): a high-incidence area
###end article-title 110
###begin article-title 111
GraphPad Software, Inc
###end article-title 111
###begin article-title 112
AliBaba 2.1
###end article-title 112
###begin article-title 113
Michael Zuker's home page
###end article-title 113
###begin article-title 114
EMBOSS, The European Molecular Biology Open Software Suite
###end article-title 114
###begin article-title 115
###xml 52 77 52 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Saccharomyces cerevisiae </italic>
###xml 46 51 <span type="species:ncbi:4932">yeast</span>
###xml 52 76 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
Inhibition of translational initiation in the yeast Saccharomyces cerevisiae as a function of the stability and position of hairpin structures in the mRNA leader
###end article-title 115
###begin article-title 116
Determinants of translational fidelity and efficiency in vertebrate mRNAs
###end article-title 116
###begin article-title 117
Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers
###end article-title 117
###begin article-title 118
###xml 63 71 <span type="species:ncbi:9606">patients</span>
Common genetic variants of TP53 and BRCA2 in esophageal cancer patients and healthy individuals from low and high risk areas of northern China
###end article-title 118
###begin article-title 119
A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis
###end article-title 119
###begin article-title 120
A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability
###end article-title 120
###begin article-title 121
BRCA2 is required for homology-directed repair of chromosomal breaks
###end article-title 121
###begin article-title 122
Lower level of BRCA2 protein in heterozygous mutation carriers is correlated with an increase in DNA double strand breaks and an impaired DSB repair
###end article-title 122
###begin article-title 123
###xml 54 59 <span type="species:ncbi:10090">mouse</span>
Analysis of DNA repair and recombination responses in mouse cells depleted for Brca2 by SiRNA
###end article-title 123

